Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial

Basit Öğe Kaydı
dc.contributor.authorCurran, Desmond
dc.contributor.authorPozzo, Carmelo
dc.contributor.authorZaluski, Jerzy
dc.contributor.authorDank, Magdalena
dc.contributor.authorBarone, Carlo
dc.contributor.authorValvere, Vahur
dc.contributor.authorYalcin, Suayib
dc.contributor.authorPeschel, Christian
dc.contributor.authorWenczl, Miklos
dc.contributor.authorGoker, Erdem
dc.contributor.authorBugat, Roland
dc.date.accessioned2019-10-27T20:46:42Z
dc.date.available2019-10-27T20:46:42Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description41st Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 13-17, 2005 -- Orlando, FLen_US
dc.description.abstractThe quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented. Patients with measurable or evaluable advanced gastric cancer received IF weekly for 6/7 weeks or CF q4 weeks. QL was assessed using the EORTC QLQ-C30 at baseline, subsequently every 8 weeks until progression and thereafter every 3 months until death. The QL data were analysed using several statistical methods including summary measures and pattern-mixture modelling. A total of 333 patients were randomised and treated (IF 170, CF 163). The time-to-progression for IF and CF was 5.0 and 4.2 months (P = 0.088), respectively. The overall compliance rates for QL questionnaire completion were 60 and 56% in the IF and CF arms, respectively. Significant treatment differences were observed for the physical functioning scale (P = 0.024), nausea\vomiting (P = 0.001) and EQ-5D thermometer (P = 0.020) in favour of the IF treatment arm. There was a trend in favour of IF over CF in time-to-progression. The IF group also demonstrated a better safety profile than CF and a better QL on a number of multi-item scales, suggesting that IF offers an alternative first-line platinum-free treatment option for advanced gastric cancer.en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.doi10.1007/s11136-009-9493-zen_US
dc.identifier.endpage861en_US
dc.identifier.issn0962-9343
dc.identifier.issn1573-2649
dc.identifier.issue7en_US
dc.identifier.pmid19568958en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage853en_US
dc.identifier.urihttps://doi.org/10.1007/s11136-009-9493-z
dc.identifier.urihttps://hdl.handle.net/11454/42446
dc.identifier.volume18en_US
dc.identifier.wosWOS:000268881000007en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofQuality of Life Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectQuality of lifeen_US
dc.subjectAdvanced gastric canceren_US
dc.subjectEORTC QLQ-C30en_US
dc.subjectEuroQoLen_US
dc.subjectIrinotecanen_US
dc.subjectCPT-11en_US
dc.titleQuality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu